Compare FINW & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINW | PLX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 182.9M |
| IPO Year | 2021 | 1996 |
| Metric | FINW | PLX |
|---|---|---|
| Price | $10.81 | $2.64 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.33 | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 801.0K |
| Earning Date | 10-28-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 0.35 | 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $41.06 | $55.77 |
| Revenue Next Year | $15.47 | N/A |
| P/E Ratio | $30.71 | ★ $10.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.64 | $1.65 |
| 52 Week High | $19.86 | $3.19 |
| Indicator | FINW | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 23.29 | 46.73 |
| Support Level | N/A | $2.59 |
| Resistance Level | $14.55 | $2.75 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 28.72 | 20.00 |
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.